Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$23.84 - $28.48 $0 - $0
0 New
0 $0
Q2 2024

Aug 14, 2024

BUY
$25.13 - $30.27 $0 - $0
0 New
0 $0
Q1 2024

May 13, 2024

BUY
$26.43 - $32.77 $0 - $0
0 New
0 $0
Q4 2023

Feb 09, 2024

BUY
$27.94 - $35.44 $0 - $0
0 New
0 $0
Q3 2023

Nov 03, 2023

BUY
$35.27 - $42.24 $0 - $0
0 New
0 $0
Q2 2023

Aug 14, 2023

BUY
$37.4 - $42.94 $0 - $0
0 New
0 $0
Q1 2023

May 11, 2023

BUY
$34.88 - $43.22 $0 - $0
0 New
0 $0
Q4 2022

Feb 14, 2023

BUY
$33.8 - $47.06 $0 - $0
0 New
0 $0
Q3 2022

Nov 14, 2022

BUY
$31.52 - $373.61 $0 - $0
0 New
0 $0
Q3 2022

Nov 10, 2022

BUY
$31.52 - $373.61 $0 - $0
0 New
0 $0
Q3 2022

Nov 10, 2022

BUY
$31.52 - $373.61 $0 - $0
0 New
0 $0
Q2 2022

Aug 12, 2022

BUY
$26.83 - $38.57 $0 - $0
0 New
0 $0
Q1 2022

May 13, 2022

BUY
$30.95 - $39.68 $0 - $0
0 New
0 $0

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Nomura Asset Management CO LTD Portfolio

Follow Nomura Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.